Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00721747
Recruitment Status : Unknown
Verified March 2012 by Grupo Oncológico Gallego.
Recruitment status was:  Active, not recruiting
First Posted : July 24, 2008
Last Update Posted : March 16, 2012
Pivotal S.L.
Information provided by (Responsible Party):
Grupo Oncológico Gallego

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Actual Primary Completion Date : January 2011
  Estimated Study Completion Date : January 2015